voyager therapeutics inc

Vision, Mission, & Strategy

Management Team

Board of Directors

Scientific Advisory Board

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Approaches

Publications & Presentations

Press Releases

Events & Presentations

Corporate Governance

Stock Information

Job Openings

Our Community

Core Values

Disclosures

Shareholder Services

Advancing transformative medicines for neurological diseases.

Neurologic diseases – which are estimated to impact more than 1 billion people globally – represent a significant burden on those who suffer from them, on their families and communities, and on the healthcare system..

Thanks to significant advances in human genetics and genomics, we now understand the molecular causes of many neurological diseases and know how to target them.

Our pipeline includes medicines targeting the genetics underlying multiple neurological diseases.

MECHANISM / INDICATION

Early Research

Late Research

IND-Enabling

WHOLLY-OWNED PIPELINE

+ SOD1 Silencing Gene Therapy (VY9323) (siRNA)  / ALS

+ Tau Silencing Gene Therapy (siRNA) / Alzheimer’s Disease

PARTNERSHIPS (REIMBURSED)

Five Gene Therapy Programs / Undisclosed Diseases Neurocrine

Undisclosed

CAPSID LICENSES

Alexion, AstraZeneca Rare Disease License

Novartis Licenses

Sangamo License

One of Voyager’s core values is “Patients First.” This means we act with urgency and drive every decision with the knowledge that patients are waiting for us.

Photo: Klaus C., living with ALS, 2023

anti-tau antibody for Alzheimer’s disease

Modality : monoclonal antibody

Target : tau protein. Designed to block the spread of pathological tau, which is closely correlated with disease progression and cognitive decline in Alzheimer’s disease.

Key Data : We believe VY-TAU01 is differentiated from other anti-tau antibodies based on the epitope it targets, which is located in the C-terminal rather than the N-terminal, mid-domain, or microtubule binding region (MTBR) region of the tau protein. At AAIC 2022 , Voyager presented data demonstrating that an anti-tau antibody delivered intravenously inhibited the spread of pathological tau by >70% in a mouse seeding model.

Alzheimer’s gene therapy early research programs

Tau knock-down program.

Indication : Alzheimer’s disease

Modality : gene therapy: novel TRACER-derived capsid with vectorized anti-tau siRNA

Target : intracellular tau

Key Data : At ASGCT 2024 , Voyager presented data demonstrating that a single IV administration of a tau silencing gene therapy candidate in a mouse model expressing human tau resulted in dose-dependent increases in vector genomes and concomitant reductions in tau mRNA levels of up to 90%, which were associated with significant reductions (50-70%) in human tau protein levels across the brain.

Status : IND anticipated in 2026

Vectorized anti-amyloid antibody program

Modality : gene therapy: novel TRACER-derived capsid with vectorized anti-A beta amyloid antibody

Target : amyloid plaques

gene therapy for Amyotrophic Lateral Sclerosis (ALS)

Indication : Amyotrophic Lateral Sclerosis (ALS)

Modality : gene therapy: novel TRACER-derived capsid with vectorized anti-SOD1 siRNA

Target : superoxide dismutase 1 (SOD1); mutations in this gene can cause toxic gain of function.

Key Data : At ASGCT 2024 , Voyager presented data demonstrating that a SOD1 RNAi transgene packaged in a second-generation TRACER capsid reduced SOD1 messenger RNA (mRNA) expression by up to 80% in non-human primate (NHP) spinal cord motor neurons following a single IV delivery at a clinically relevant dose of 3E13 vg/kg.

Status : IND submission expected in mid-2025.

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

Bid Price and Ask Price

The  bid  &  ask  refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing to pay, whereas the ask is the lowest amount that a seller is currently willing to sell. The numbers next to the bid/ask are the “ size ”. The bid size displays the total amount of desired shares ... Read More. to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time. The  bid-ask spread  can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a  market order  or  limit order  when trading, helping you to optimize your price and have a successful order execution. Real-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit  Nasdaq Data Link's products page . ... Read Less.

• After-Hours
• Press Releases
• Analyst Research
• Dividend History
• Historical Quotes
• Historical NOCP
• P/E & PEG Ratios
• Option Chain
• Short Interest
• Institutional Holdings
• Insider Activity
• SEC Filings
• Revenue EPS

Symbol Search

Recently viewed.

Analyze your stocks, your way

Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.

Latest News

This data feed is not available at this time.

Trending Stocks

Trending etfs, trending indexes.

• Real-time Data is provided using Nasdaq Last Sale Data

Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at  data.nasdaq.com .

• Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

• Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .

We've detected unusual activity from your computer network

To continue, please click the box below to let us know you're not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .

For inquiries related to this message please contact our support team and provide the reference ID below.

• Get 7 Days Free

Voyager Therapeutics Inc VYGR

About quantitative ratings.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

Voyager therapeutics to present at multiple virtual investor conferences, voyager therapeutics announces appointment of nathan jorgensen as chief financial officer, voyager therapeutics announces first participants dosed in single ascending dose trial of vy-tau01 for the treatment of alzheimer’s disease, voyager therapeutics reports first quarter 2024 financial and operating results, voyager therapeutics presents data for second-generation, tracer™-generated capsids and cns gene therapy programs advancing toward clinical trials at the asgct 27th annual meeting, voyager therapeutics announces first quarter 2024 conference call and webcast, voyager therapeutics to present broad set of translational data supporting iv-delivered, cns gene therapy programs advancing toward clinical trials at the asgct 27th annual meeting, voyager therapeutics announces selection of development candidate for gba1 program in collaboration with neurocrine biosciences, triggering milestone payment, trading information, key statistics, company profile, comparables.

• Morphic Holding Inc MORF
• DICE Therapeutics Inc — DICE
• Rhythm Pharmaceuticals Inc RYTM

Financial Strength

Profitability, biotechnology industry comparables, sponsor center.

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Voyager Therapeutics Inc

Ever heard of finviz*elite.

Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more. Become Elite and make informed financial decisions.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

How to make sure you don’t get underpaid when it comes to state pension

Getting less than you were expecting could come as a nasty surprise but there are things you can do about it

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

“Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurotherapeutics based on genetically-validated targets,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Nathan’s highly differentiated background integrates operational and strategic leadership, a deep understanding of value creation in the life sciences, and expertise in neuroscience, which will be critical as we advance additional programs into the clinic and build a multi-modality neurotherapeutics company.”

As CFO at Vor Bio, Jorgensen oversaw finance, communications, facilities, GMP, and IT and raised over $400 million in public and private financings. Prior to this, he managed global public and private healthcare investing, including in early-stage biotech companies, for the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Previously, Jorgensen led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC, a diversified global investment firm. Before joining Calamos, he covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated. Prior to entering the financial sector, Jorgensen investigated the pathobiology of Parkinson’s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John’s University.

“Voyager is advancing a suite of transformative neurogenetic medicines, with multiple opportunities to create value for patients and for shareholders,” said Jorgensen. “I am excited about the possibilities offered by Voyager’s differentiated platform, along with its unparalleled team in the field of neuroscience. The pipeline is poised to tackle the delivery hurdles that have held back progress in neurology, and I look forward to applying my strategic financial expertise to enable the team to execute and deliver on the promise of its tremendous science.”

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “potential,” “anticipate,” “expect,” “will,” “may,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding the timing and effective date of the appointment of Dr. Jorgensen, the contributions Dr. Jorgensen may make in his role with the Company, and Voyager’s ability to advance additional programs into the clinic and build a multi-modality neurotherapeutics company are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the initiation, timing, conduct and outcomes of Voyager’s preclinical and clinical studies; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts Trista Morrison, NACD.DC, [email protected] Investors: Adam Bero, Ph.D., [email protected] Media: Brooke Shenkin, [email protected]

Latest stories

British couple become wealthier than larry fink after £2.5bn blackrock deal.

A husband and wife duo who built an outdoor theatre on the grounds of their Suffolk farm estate have been catapulted into Britain’s rich list after netting £2bn from the sale of their financial data business.

Family with £62k income using Klarna for food shop due to cost of living crisis

A mum-of-five with a £62k household income has resorted to using Klarna to afford her food shop - due to the cost-of-living crisis. Laura Caine, 40, struggles to cover her family's monthly outgoings using her £1k-a-month universal credit payment and her husband Martin's £50k games programmer salary. The couple have five children - aged 18 to nine - and say feeding the brood three meals a day gets expensive so they have had to use the buy-now-pay-later service. In recent months Laura says she had to use Klarna to afford groceries as she "can't afford" to pay for a big shop upfront. Laura claims both she and Martin have both maxed out their credit cards after their energy bill shot up to £450-a-month from £200.

A 9.9% dividend yield! Is this hidden FTSE passive income gem too good to miss?

This FTSE 100 insurance and investment firm has one of the highest yields in the index, looks set for stellar growth, and appears undervalued to me. The post A 9.9% dividend yield! Is this hidden FTSE passive income gem too good to miss? appeared first on The Motley Fool UK.

Major banks slash mortgage rates as Labour victory looms

Three major lenders have cut mortgage rates ahead of an expected Labour victory this week.

This tax has been tinkered with for 60 years – please Labour, leave it alone

Every chancellor wants to make their mark on history, particularly following a change in colour of the Government.

Banks, homebuilders and retailers in focus as London markets brace for Labour election victory

The UK general election is in focus this week as investors brace for a widely expected Labour landslide that could share price moves across the FTSE 100.

2 boring yet consistent dividend shares investors should consider buying in July

Some dividend shares offer the potential for regular returns, with a good record and bright future prospects. The post 2 boring yet consistent dividend shares investors should consider buying in July appeared first on The Motley Fool UK.

How Britain’s wealthiest savers are preparing for a Labour government

As Conservative grandees fret about a Labour “forever government” after this week’s election, Britain’s most affluent savers and investors are busy making the most of tax reliefs while they still can.

Could the BAE Systems share price be about to collapse?

The BAE Systems share price has pulled back by 8% over the past month. Our writer considers whether this may be the start of a bigger trend. The post Could the BAE Systems share price be about to collapse? appeared first on The Motley Fool UK.

Labour stamp duty crackdown will make first-time buyers £7,000 worse off

First-time buyers in London will be nearly £7,000 worse off under Labour as the party is set to overhaul the stamp duty exemption.

Should I buy Ocado shares after a 90% drop?

Ocado shares have taken a huge hit over the last three-and-a-half years, losing around 90% of their value. Should Edward Sheldon buy them now? The post Should I buy Ocado shares after a 90% drop? appeared first on The Motley Fool UK.

These 3 passive income shares could generate a ton of dividends

Millions of us invest for dividends. Here, our writer highlights three passive income shares that deliver index-topping returns for investors. The post These 3 passive income shares could generate a ton of dividends appeared first on The Motley Fool UK.

The Wealthiest Person in Ireland

We recently compiled a list of the 11 Wealthiest People in Ireland and in this article, we will look at the richest person in Ireland. Ireland’s Global Positioning Ireland is the second richest country in the world boasting a GDP per capita of $143,179 and a wealth per adult of $247,080. The country has demonstrated […]

Coinbase Stock Drops Along With Bitcoin and Ether. This Could Be a Crypto Catalyst.

The two cryptocurrencies were down in early trading Tuesday. Investors are anticipating the next wave of exchange-traded funds.

I’d aim for a second income of £1,200 a month with this high-yield dividend stock

Investing in dividend stocks via a Stocks and Shares ISA is a great way to build a second income stream, according to this Fool. Here’s one stock to consider. The post I’d aim for a second income of £1,200 a month with this high-yield dividend stock appeared first on The Motley Fool UK.

Are FTSE 100 shares STILL cheap? I think so, and here’s one to consider buying in July

The FTSE 100's up 442 points this year, but bargains remain. Mark Hartley reveals one of his favourite value stocks this month. The post Are FTSE 100 shares STILL cheap? I think so, and here’s one to consider buying in July appeared first on The Motley Fool UK.

2 shares I’d give a wide berth to in today’s stock market

The UK stock market is brimming with promising long-term investment opportunities. But I wouldn’t say that these two shares are the ones. The post 2 shares I’d give a wide berth to in today’s stock market appeared first on The Motley Fool UK.

Best savings accounts for 2024

Regardless of why you’re saving – for a house, holiday, or as a buffer to cover emergencies – you’ll want to make sure your money is working as hard as possible.

Airbus jet deliveries rise, but headwinds mount

STORY: Airbus delivered more jets over the first half of the year, but it's battling mounting headwinds. Industry sources estimate the aerospace giant handed over about 323 new aircraft. That would be up about 2% on last year, with official figures expected next week. But the sources estimate deliveries fell short of targets in June. That would tally with a warning from Airbus last week that it was cutting its goals for the year. It now aims to deliver 770 jets, instead of the 800 initially planned. The firm cited a shortage of engines, structural parts and interiors. As a result it put back plans to raise output of its best-selling A320neo family of jets. It still expects to hit a record rate of 75 per month, but not until 2027 - a year later than expected. Right now it makes 50 per month. There was no comment on the latest reports from Airbus. But some analysts are already cutting their forecasts for its output next year.

Best US stocks to buy in July

We asked our freelance writers to reveal the top US stocks they’d buy in July, which included two Share Advisor 'Fire' recommendations! The post Best US stocks to buy in July appeared first on The Motley Fool UK.

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NVIDIA CORPORATION
• META PLATFORMS, INC.
• AMD (ADVANCED MICRO DEVICES)
• TESLA, INC.
• BLACKROCK, INC.
• NIPPON ACTIVE VALUE FUND PLC
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Yield Curve
• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Dividend Aristocrats
• Quality stocks at a reasonable price
• Multibaggers
• Undervalued stocks
• Circular economy
• The Cannabis Industry
• Powerful brands
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Solar energy
• Warren Buffett
• Wind energy
• Serial buyers
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Y-mAbs Therapeutics, Inc.

Us9842411095, biotechnology & medical research.

• Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Y-mAbs Therapeutics, Inc. announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc. Prior to Voyager, Mr. Pfreundschuh served as Chief Financial Officer, Head of Business Development at Frequency Therapeutics, Inc., and before that, he served as Chief Financial Officer, Chief Compliance Officer and Corporate Secretary at UroGen Pharma Ltd. He also served in executive roles at Sucampo Pharmaceuticals, Inc. Immunomedics, Inc. and Circulite, Inc. Earlier, Mr. Pfreundschuh held progressively senior roles across Finance, Commercial Operations, and Business Development at Johnson & Johnson and AstraZeneca. He began his career as an auditor at Ernst & Young, LLP.

Mr. Pfreundschuh currently serves on the Board of Directors of NorthStar Medical Technologies, LLC, the parent company of NorthStar Medical Radioisotopes, LLC. He graduated from Rutgers University School of Business with a Bachelor of Science in Accounting and earned a Master of Business Administration from Rider University. Mr. Pfreundschuh is a Certified Public Accountant in the State of New Jersey.

Mr. Pfreundschuh will be based in Y-mAbs? New York and New Jersey offices.

Latest news about Y-mAbs Therapeutics, Inc.

Chart y-mabs therapeutics, inc..

Company Profile

Income statement evolution, ratings for y-mabs therapeutics, inc., analysts' consensus, eps revisions, quarterly earnings - rate of surprise, sector bio therapeutic drugs.

• Stock Market
• News Y-mAbs Therapeutics, Inc.

Vision, Mission, & Strategy

Management Team

Board of Directors

Scientific Advisory Board

Core Values

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Delivery

Publications & Presentations

Press Releases

Events & Presentations

Stock Information

Shareholder Services

Job Openings

Our Community

Mission & Values

Disclosures

Release Details

Voyager therapeutics enters capsid license agreement and strategic collaboration with novartis to advance novel gene therapies.

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy -

- Voyager to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties -

LEXINGTON, Mass. , Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG , a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.

Alfred W. Sandrock , Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Combining the proven capabilities of Novartis in gene therapy development and commercialization with Voyager’s next-generation TRACER capsids and payloads could enable the advancement of important new therapies for patients. In addition, the consideration Voyager will receive from this collaboration will strengthen our balance sheet and extend our runway into mid-2026.”

Fiona Marshall , President of Biomedical Research at Novartis. “We believe Voyager’s TRACER capsids hold promise for enabling next-generation gene therapies for diseases of the central nervous system, aligning well with our deep neuroscience expertise and gene therapy leadership at Novartis.”

Novartis previously exercised options to license novel capsids generated from Voyager’s TRACER capsid discovery platform for use in gene therapy programs against two undisclosed neurological disease targets.

Collaboration Details and Financial Terms Under the terms of the agreement, Novartis has agreed to pay Voyager $100 million of consideration up front, including a $20 million purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids. Novartis will obtain target-exclusive access to Voyager’s TRACER capsids related to SMA for the duration of the agreement and will be responsible for all development and commercialization. Novartis will also receive worldwide rights to Voyager’s AAV gene therapy for HD, leveraging Voyager’s TRACER capsids and proprietary payloads. Voyager will be responsible for preclinical advancement and Novartis will be responsible for all clinical development and commercialization for the HD program.

Chestnut Partners served as exclusive financial advisor to Voyager on this transaction.

About the TRACER™ Capsid Discovery Platform Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs). In preclinical studies, TRACER generated capsids have demonstrated widespread gene expression in the CNS compared to conventional AAV capsids as well as cell- and tissue-specific transduction, including to areas of the brain that have been traditionally difficult to reach, while de-targeting the liver and dorsal root ganglia. As part of its external partnership strategy, Voyager has established multiple collaboration agreements providing access to its next-generation TRACER capsids to potentially enable its partners’ gene therapy programs to treat a variety of diseases.

About Voyager Therapeutics Voyager Therapeutics , Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG ; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit  www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “aims,” “will,” “could,” or “potential,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding the potential for Voyager’s collaboration with Novartis to enable the discovery, development and advancement of important new therapies for patients with spinal muscular atrophy and Huntington’s disease; Voyager’s cash runway and Voyager’s ability to generate sufficient cash resources to enable it to continue its business and operations; the potential of Voyager’s intravenous TRACER capsids to enable high brain penetration, target and de-target certain tissues, and enable next generation gene therapies for diseases of the central nervous system; and Voyager’s ability to modify the course of, and ultimately cure, neurological diseases are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the initiation, timing, conduct and outcomes of Voyager’s preclinical studies; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s current licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Andrew Funderburk [email protected]   

Peg Rusconi [email protected]

Source: Voyager Therapeutics, Inc.

• Press Releases
• Investor Relations

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Mike Rossi , President and Chief Executive Officer.

Mr. Rossi . “With Peter on board as our new U.S. -based Chief Financial Officer, we believe we are in a strong position to make strategic decisions that will serve our mission of improving the lives of patients with cancer and other serious diseases. Peter brings a wealth of leadership experience across the healthcare sector with deep experience in developing and commercializing novel pharmaceutical products, and we are excited to welcome him to our team.”

Mr. Pfreundschuh is a Certified Public Accountant in the State of New Jersey .

Mr. Pfreundschuh . “With a solid financial foundation fueled by the growing commercial success of DANYELZA ® on a global scale, I believe Y-mAbs is well positioned to further advance our SADA-PRIT technology platform and materially change the way we think about and use radiopharmaceutical therapies to improve patient lives. I look forward to working closely with the executive leadership team and others across the organization as we continue to build upon the great success at Y-mAbs.”

Mr. Pfreundschuh will be based in Y-mAbs’ New York and New Jersey offices.

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy, and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) ​Pretargeted Radioimmunotherapy Platform (“PRIT”)​ and bispecific antibodies generated using the Y-BiClone platform. The Company’s product pipeline includes the anti-GD2 therapy DANYELZA ® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about the Company’s expectation that, with its new Chief Financial Officer, it is in a position to make strategic decisions that will serve its mission of improving the lives of patients with cancer and other serious diseases; the future of the Company’s business, including with respect to expansion and its goals; the promising future of the Company; expectations with respect to the Company’s products and product candidates, including potential territory expansion of DANYELZA and the potential market opportunity related thereto and the advancement and potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications thereof; statements with respect to DANYELZA as a growing commercial product and SADA as a differentiated radioimmunotherapy platform; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

DANYELZA ® and Y-mAbs ® are registered trademarks of Y-mAbs Therapeutics, Inc.

Courtney Dugan VP, Head of Investor Relations [email protected]

Source: Y-mAbs Therapeutics, Inc.

You are leaving this website

You are about to leave ymabs.com. The link will take you to a website that may be maintained by a third party, which is solely responsible for its content. Y-mAbs Therapeutics, Inc provides this link as a service to its web visitors, and is not responsible for the privacy policy or terms of use of any third-party website.

• Y-mAbs Therapeutics-stock
• News for Y-mAbs Therapeutics

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.

“Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA ® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pretargeted Radioimmunotherapy, or SADA-PRIT, technology platform,” said Mr. Rossi. “With Peter on board as our new U.S.-based Chief Financial Officer, we believe we are in a strong position to make strategic decisions that will serve our mission of improving the lives of patients with cancer and other serious diseases. Peter brings a wealth of leadership experience across the healthcare sector with deep experience in developing and commercializing novel pharmaceutical products, and we are excited to welcome him to our team.”

Mr. Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc. Prior to Voyager, Mr. Pfreundschuh served as Chief Financial Officer, Head of Business Development at Frequency Therapeutics, Inc., and before that, he served as Chief Financial Officer, Chief Compliance Officer and Corporate Secretary at UroGen Pharma Ltd. He also served in executive roles at Sucampo Pharmaceuticals, Inc. Immunomedics, Inc. and Circulite, Inc. Earlier, Mr. Pfreundschuh held progressively senior roles across Finance, Commercial Operations, and Business Development at Johnson & Johnson and AstraZeneca. He began his career as an auditor at Ernst & Young, LLP. Mr. Pfreundschuh currently serves on the Board of Directors of NorthStar Medical Technologies, LLC, the parent company of NorthStar Medical Radioisotopes, LLC. He graduated from Rutgers University School of Business with a Bachelor of Science in Accounting and earned a Master of Business Administration from Rider University. Mr. Pfreundschuh is a Certified Public Accountant in the State of New Jersey.

“I am thrilled to join the Y-mAbs team during this pivotal time for the company,” said Mr. Pfreundschuh. “With a solid financial foundation fueled by the growing commercial success of DANYELZA ® on a global scale, I believe Y-mAbs is well positioned to further advance our SADA-PRIT technology platform and materially change the way we think about and use radiopharmaceutical therapies to improve patient lives. I look forward to working closely with the executive leadership team and others across the organization as we continue to build upon the great success at Y-mAbs.”

Mr. Pfreundschuh will be based in Y-mAbs’ New York and New Jersey offices.

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy, and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) ​Pretargeted Radioimmunotherapy Platform (“PRIT”)​ and bispecific antibodies generated using the Y-BiClone platform. The Company’s product pipeline includes the anti-GD2 therapy DANYELZA ® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about the Company’s expectation that, with its new Chief Financial Officer, it is in a position to make strategic decisions that will serve its mission of improving the lives of patients with cancer and other serious diseases; the future of the Company’s business, including with respect to expansion and its goals; the promising future of the Company; expectations with respect to the Company’s products and product candidates, including potential territory expansion of DANYELZA and the potential market opportunity related thereto and the advancement and potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications thereof; statements with respect to DANYELZA as a growing commercial product and SADA as a differentiated radioimmunotherapy platform; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

DANYELZA ® and Y-mAbs ® are registered trademarks of Y-mAbs Therapeutics, Inc.

Investor Contact: Courtney Dugan VP, Head of Investor Relations [email protected]

Y-mAbs Therapeutics News MORE

Related stocks.